#Impact: Major Publications 

## Case Studies
Numerous coMMpass derived reports have significantly shifted the understanding of myeloma subtypes, therapeutic targets, immune status or risk stratification sufficiently to enabling incorporation to drug development or therapeutic strategies.  

These include:

### 1. CGS High risk provides an improved strategy to identify patients with a poor prognosis despite receipt of modern triplet or quadruplet therapies. This integrates clinical, cytogenetic and genomics characteristics and forms the basis of new and ongoing High Risk focused clinical trials.  

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC.J Clin Oncol. 2025 Aug 20;43(24):2739-2751. doi: 10.1200/JCO-24-01893. Epub 2025 Jun 9.PMID: 40489728

### 2. Disease transitions and therapeutic targets in the tumor and immune compartments J&J report describes immune disease transitions for smoldering myeloma and simmune disease transitions for smoldering myeloma and multiple myeloma integrating coMMpass tumor and single cell immune data, including the clinical outcomes across rapid and slow progression disease subtypes. 

Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.

- Bergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, Vanhoof G, Smets T, Verbist B, De Maeyer D, Van Houdt J, Van der Borght K, Verona R, Heidrich B, Kurth W, Delforge M, Meuleman N, Van Droogenbroeck J, Vlummens P, Heuck CJ, Beguin Y, Bahlis N, Casneuf T, Caers J.
- PLoS Genet. 2025 Oct 7;21(10):e1011848. doi: 10.1371/journal.pgen.1011848. PMCID: PMC12558612

### 3. Defining resistance to frontline quad therapies / immunotherapy Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.

- Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, Ghamlouch H, Blaney P, Ziccheddu B, Cirrincione A, Chojnacka M, Wang Y, Siegel A, Hoffman JE, Kazandjian D, Hassoun H, Guzman E, Mailankody S, Shah UA, Tan C, Hultcrantz M, Scordo M, Shah GL, Landau H, Chung DJ, Giralt S, Zhang Y, Arbini A, Gao Q, Roshal M, Dogan A, Lesokhin AM, Davies FE, Usmani SZ, Korde N, Morgan GJ, Landgren O.
- Nat Cancer. Author manuscript. 2023 Nov 9;4(12):1660-1674. doi: 10.1038/s43018-023-00657-1.  PMCID: PMC12065606


### 4. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.

- Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, Kawehi Kelii KM, Dalal R, Ramos E, Vijayanarayanan A, Salangsang F, Phojanakong P, Serrano JAC, Zakraoui O, Tariq I, Steri V, Shanmugam M, Boise LH, Kortemme T, Stieglitz E, Licht JD, Karlon WJ, Barwick BG, Wiita AP.
- bioRxiv [Preprint]. 2024 Feb 28:2024.02.24.581875. doi: 10.1101/2024.02.24.581875. PMCID: PMC10925123

### 5. Characterization of TP53 loss and outcome Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.

- Nesnadna R, Petrackova A, Minarik J, Latal V, Manakova J, Papajik T, Kriegova E. Mol Med. 2025 Nov 29;32(1):3. doi: 10.1186/s10020-025-01392-2. PMCID: PMC12771809
- Multiple myeloma (MM) with high-risk (HR) genetic abnormalities has poor prognosis, despite the use of novel therapeutic agents. 
- atients with multi-hit TP53 (10.4%) had the shortest PFS and OS compared with those with single HR abnormalities (p 0.011)

## Additional Publications 